Prof. Dr. Gerald Reischl

Personal Data

Status/Function:	Head of Radiopharmacy
Scientific Focus:	Radiopharmaceutical Sciences, PET Isotope Production Methods, PET Tracer Development, Small Molecules, Antibodies, Imaging of Hypoxia / Inflammation / Infectious Diseases, Preclinical Evaluation and Translation into Clinical Application
Phone:	+49-7071-29 80531
Fax:	+49-7071-29 5264
Email:	gerald.reischl@uni-tuebingen.de

Education and Qualifications

2021	Appointment as “Außerplanmäßiger Professor” – Associate Professor
2009	Postdoctoral Thesis (Habilitation and Venia Legendi) in Radiopharmacy, Medical Faculty, Eberhard Karls University Tübingen, Mentor: Prof. Dr. H.-J. Machulla
1994	Doctoral Thesis in Organic Chemistry, University of Tübingen, Mentor: Prof. Dr. A. Rieker
1983 - 1990	University of Tübingen, Diploma of Chemistry

Work Experience

2009 – 2016	Leading Involvement in Design, Planning, Building, Qualification of the GMP Facility of the Radiopharmacy (ca. 400 sqm, 10 Hot Cells, 2 Isolators) Authority Acceptance (Minor Revision) September 2016
2013	Research Visit at the Austin Health, University of Melbourne, Victoria, AUS
2012	Expert Mission on behalf of the International Atomic Energy Agency (IAEA) at the Nuclear Research Centre (IPEN) São Paulo, Brazil
Since 2008	Head of Radiopharmacy, Department of Radiology, Eberhard Karls University Tübingen • Update Marketing License for [^{18}F]FDG • Manufacturing Licenses for Numerous Radiopharmaceuticals for Clinical Trials and Clinical Application • Selling of Radiopharmaceuticals to External Customers
2005	Research Sabbatical at the Peter MacCallum Cancer Centre, Melbourne, AUS
Since 2004	Deputy Head of Radiopharmacy, Department of Radiology of University Tübingen
1998 – 2004	Research Fellow, Radiopharmacy, University of Tübingen
1995 – 1998	Postdoctoral Research Fellow (DFG grant 1997/98) at Radiopharmacy, PET Center, University of Tübingen

Teaching Experience

Since 2011	Teaching at MTA School (Medical Technical Radiology Assistants)
Since 2010	Regular Courses for External Radiochemists and –pharmacists for IAEA
Since 2002	Radiation Safety Courses, Isotope Laboratory, University of Tübingen
Since 2000	University of Tübingen, Medical Faculty and Faculty of Mathematics and Natural Sciences, mostly Curricular but also non-Curricular

Additional Qualifications and Skills

2022	Organization of an International Scientific Radiochemistry and –pharmacy conference AGRR 2022 (ca. 200 participants)
2020	Guest Editor for a 2nd Special Issue in *Pharmaceuticals* on "Novel Radiopharmaceuticals"
2020	Invited Contribution of a book chapter to "Encyclopedia of Nuclear Medicine and Molecular Imaging", Elsevier
Since 2020	Editorial Board of "Pharmaceuticals", IF=4.6 (2022), MDPI, Switzerland
2019 - 2022	Member of Steering Committee of the Excellence Cluster "iFIT", University of Tübingen
Since 2019	Member of the Board of the German Pharmaceutical Society (DPhG)
Since 2019	Chair of the Consortium "Radiopharmacy" of DPhG
2019	Invited Contribution to a Special Issue on "Radiopharmaceutical Sciences" in *Journal of Labelled Compounds and Radiopharmaceuticals*
2018	Guest Editor for a Special Issue in *Pharmaceuticals* on "Novel Radiopharmaceuticals"
2018	Invited Contribution to a Special Issue on "Radiopharmacy" in *Der Nuklearmediziner*
2012 - 2021	Editorial Board of "Applied Radiation and Isotopes", Elsevier, Netherlands
2010	Organization of an International Scientific Radiochemistry and –pharmacy conference AGRR 2010 (ca. 200 participants)
Since 2008	Qualified Person, Radiopharmacy, University of Tübingen
2006 - 2022	Member of the Managing Board of the Consortium "Radiochemistry / Radiopharmacy" within the German Society of Nuclear Medicine
Since 1999	Head of Quality Control and Radiation Safety Manager, Radiopharmacy, University of Tübingen

Publications

Year	Number	Title	IF
2023	116	McKay NS, Gordon BA, Hornbeck RC, Dincer A, Flores S, Keefe SJ, Joseph-Mathurin N, Jack CR, Koeppe R, Millar PR, Ances BM, Chen CD, Daniels A, Hobbs DA, Jackson K, Koudelis D, Massoumzadeh P, McCullough A, Nickels ML, Rahmani F, Swisher L, Wang Q, Allegri RF, Berman SB, Brickman AM, Brooks WS, Cash DM, Chhatwal JP, Day GS, Farlow MR, la Fougère C, Fox NC, Fulham M, Ghetti B, Graff-Radford N, Ikeuchi T, Klunk W, Lee JH, Levin J, Martins R, Masters CL, McConathy J, Mori H, Noble JM, Reischl G, Rowe C, Salloway S, Sanchez-Valle R, Schofield PR, Shimada H, Shoji M, Su Y, Suzuki K, Vöglein J, Yakushev I, Cruchaga C, Hassenstab J, Karch C, McDade E, Perrin RJ, Xiong C, Morris JC, Bateman RJ, Benzinger TLS; (2023)	28.771

Dominantly Inherited Alzheimer Network. Positron emission tomography and magnetic resonance imaging methods and datasets within the Dominantly Inherited Alzheimer Network (DIAN).
Nat Neurosci. 2023 Aug;26(8):1449-1460.

115 Trautwein NF, Reischl G, Seitz C, Dittmann H, Seith F, Scheuermann S, Feuchtinger T, Dombrowski F, Handgretinger R, Fuchs J, Pichler B, Fougère C, Schwenck J. (2023) 11.082
First-in-Humans PET/MRI of In Vivo GD2 Expression in Osteosarcoma.
J Nucl Med. 2023 Feb;64(2):337-338.

114 Ionescu TM, Amend M, Watabe T, Hatazawa J, Maurer A, Reischl G, Pichler BJ, Wehrl HF, Herfert K. (2023) 11.082
Neurovascular Uncoupling: Multimodal Imaging Delineates the Acute Effects of 3,4-Methylenedioxymethamphetamine.
J Nucl Med. 2023 Mar;64(3):466-471.

113 Isser S, Maurer A, Reischl G, Schaller M, Gonzalez-Menendez I, Quintanilla-Martinez L, Gawaz M, Pichler BJ, Beziere N. (2023) 11.082
Radiolabeled GPVI-Fc for PET Imaging of Multiple Extracellular Matrix Fibers: A New Look into Pulmonary Fibrosis Progression.
J Nucl Med. 2023 Jun;64(6):940-945.

112 Feil S, Stowbur D, Schörg BF, Ehrlichmann W, Reischl G, Kneilling M, Pichler BJ, Feil R. (2023) 23.213
Noninvasive Detection of Smooth Muscle Cell-Derived Hot Spots to Study Atherosclerosis by PET/MRI in Mice.
Circ Res. 2023 Mar 17;132(6):747-750.

111 Schwenck J, Sonanini D, Seyfried D, Ehrlichmann W, Kienzle G, Reischl G, Krezer P, Wilson I, Korn R, Gonzalez-Menendez I, Quintanilla-Martinez L, Seith F, Forschner A, Eigentler T, Zender L, Röcken M, Pichler BJ, Flatz L, Kneilling M, la Fougere C. (2023) 11.600
In vivo imaging of CD8+ T cells in metastatic cancer patients: first clinical experience with simultaneous [89Zr] Zr-Df-IAB22M2C PET/MRI.
Theranostics. 2023 Apr 17;13(8):2408-2423.

2022

110 Zippel C, Ermert J, Patt M, Gildehaus FJ, Ross T.L., Reischl G, Kuwert T, Solbach C, Neumaier B, Kiss O, Mitterhauser M, Wadsak W, Schibli R, Kopka K. (2022)
Cyclotrons Operated for Nuclear Medicine and Radiopharmacy in the German Speaking D-A-CH Countries: An Update on Current Status and Trends.
Front. Nucl. Med., 2022 Apr 14; 2
https://doi.org/10.3389/fnume.2022.850414

109 Griessinger J, Schwab J, Chen Q, Kühn A, Cotton J, Bowden G, Preibsch H, Reischl G, Quintanilla-Martinez L, Mori H, Dang AN, Kohlhofer U, Aina OH, Borowsky AD, Pichler BJ, Cardiff RD, Schmid AM. (2022) 7.519
Intratumoral in vivo staging of breast cancer by multi-tracer PET and advanced analysis.
NPJ Breast Cancer. 2022 Mar 24;8(1):41.

108 Welz S, Paulsen F, Pfannenberg C, Reimold M, Reischl G, Nikolaou K, La Fougère C, Alber M, Belka C, Zips D, Thorwarth D. (2022) 6.901
Dose escalation to hypoxic subvolumes in head and neck cancer: A randomized phase II study using dynamic [18F] FMISO PET/CT.

		Radiother Oncol. 2022 Jun; 171:30-36.	
	107	Schwenck J, Maurer A, Beziere N, Fiz F, Boschetti F, Geistlich S, Seyfried D, Gunzer M, Reischl G, Wehrmüller J, Ehrlichmann W, Horger M, Gatidis S, Davies G, Vogel W, la Fougere C, Pichler BJ, Thornton C. (2022) Antibody-guided Molecular Imaging of Aspergillus Lung Infections in Leukemia Patients. **J Nucl Med**. 2022 Jul 21: jnumed.121.263251	11.082
	106	Schmitt J, Schwenck J, Maurer A, Przybille M, Sonanini D, Reischl G, Wehrmüller JE, Quintanilla-Martinez L, Gillies SD, Krueger MA, Schaefer JF, la Fougère C, Handgretinger R, Pichler BJ. (2022) Translational immunoPET imaging using a radiolabeled GD2-specific antibody in neuroblastoma. **Theranostics.** 2022 Jul 18;12(13):5615-5630.	11.600
	105	Zhang Y., Kupferschläger J., Lang P., Reischl G., Handgretinger R., la Fougère C., Dittmann H. (2021). 131Iodine-GD2-ch14.18 scintigraphy to evaluate option for radioimmunotherapy in patients with advanced tumors. **J Nucl Med.** 2022 Feb;63(2):205-211.	11.082
2021	104	Kullmann S, Blum D, Jaghutriz BA, Gassenmaier C, Bender B, Häring HU, Reischl G, Preissl H, la Fougère C, Fritsche A, Reimold M, Heni M (2021). Central Insulin Modulates Dopamine Signaling in the Human Striatum. **J Clin Endocrinol Metab**. 2021 Sep 27;106(10):2949-2961.	5.958
	103	Smaxwil C., Aschoff P., Reischl G., Busch M., Wagner J., Altmeier J., Ploner O., Zielke A. (2021). [18F]fluoro-ethylcholine-PET Plus 4D-CT (FEC-PET-CT): A Break-Through Tool to Localize the "Negative" Parathyroid Adenoma. One Year Follow Up Results Involving 170 **Patients. J. Clin. Med.** 10: 1648.	4.241
2020	102	Socarrás Fernández J.A., Mönnich D., Leibfarth S., Welz S., Zwanenburg A., Leger S., Löck S., Pfannenberg C., la Fougère C., Reischl G., Baumann M., Zips D., Thorwarth D. (2020). Comparison of patient stratification by computed tomography radiomics and hypoxia positron emission tomography in head-and-neck cancer radiotherapy. **Phys. Imaging Radiat. Oncol.** 15: 52-59.	Cite score 2,3
	101	Kaufmann S., Kruck S., Gatidis S., Hepp T., Thaiss W.M., Hennenlotter J., Schwenck J., Scharpf M., Nikolaou K., Stenzl A., Reischl G., la Fougère C., Bedke J. (2020). Simultaneous whole-body PET/MRI with integrated multiparametric MRI for primary staging of high-risk prostate cancer. **World J. Urol.** 38: 2513-2521.	3.217
2019	100	Kuçi Z., Ehrlichmann W., Sauer J., Handgretinger R., Bruchelt G., Reischl G. (2019). Fast enzymatic synthesis of n.c.a. 6-[18F]fluorodopamine (FDA) from n.c.a. 6-[18F]FDOPA and the fate of 6-FDOPA and 6-FDA in neuroblastoma and Caki-1 cells after their uptake. **J. Labelled Comp. Radiopharm**. 62: 438-447.	1.809
	99	Guenthoer P., Fuchs K., Reischl G., Quintanilla-Martinez L., Gonzalez-Menendez I., Laufer S., Pichler B.J., Kneilling M. (2019).	3.238

Evaluation of the therapeutic potential of the selective p38 MAPK inhibitor Skepinone-L and the dual p38/JNK 3 inhibitor LN 950 in experimental K/BxN serum transfer arthritis.
Inflammopharmacology. 27: 1217-1227.

98 Smolka M.N., Reimold M., Kobiella A., Reischl G., Rietschel M., Heinz A. (2019). 3.853
Smoking moderates association of 5-HTTLPR and in vivo availability of serotonin transporters.
Eur. Neuropsychopharmacol. 29: 171-178.

97 Thorwarth D., Welz S., Mönnich D., Pfannenberg C., Nikolaou K., Reimold M., la Fougère C., Reischl G., Mauz P.S., Paulsen F., Alber M., Belka C., Zips D. (2019). 7.887
Prospective Evaluation of a Tumor Control Probability Model Based on Dynamic 18F-FMISO PET for Head and Neck Cancer Radiotherapy.
J. Nucl. Med. 60: 1698-1704.

96 Schwenck J., Olthof S.C., Pfannenberg C., Reischl G., Wegener D., Marzec J., Bedke J., Stenzl A., Nikolaou K., la Fougère C., Zips D., Müller A.C. (2019). 7.887
Intention-to-Treat Analysis of 68Ga-PSMA and 11C-Choline PET/CT versus CT for Prostate Cancer Recurrence After Surgery.
J. Nucl. Med. 60: 1359-1365.

95 Bezière N., Fuchs K., Maurer A., Reischl G., Brück J., Ghoreschi K., Fehrenbacher B., Berrio D.C., Schenke-Layland K., Kohlhofer U., Quintanilla-Martinez L., Gawaz M., Kneilling M., Pichler B. (2019). 8.579
Imaging fibrosis in inflammatory diseases: Targeting the exposed extracellular matrix.
Theranostics 9: 2868-2881.

94 Hoffmann S.H.L., Reck D.I., Maurer A., Fehrenbacher B., Sceneay J.E., Poxleitner M., Öz H.H., Ehrlichmann W., Reischl G., Fuchs K., Schaller M., Hartl D., Kneilling M., Möller A., Pichler B.J., Griessinger C.M. (2019). 8.579
Visualization and quantification of in vivo homing kinetics of myeloid-derived suppressor cells in primary and metastatic cancer.
Theranostics 9: 5869-5885.

93 Maier F.C., Schweifer A., Damaraju V.L., Cass C.E., Bowden G.D., Ehrlichmann W., Kneilling M., Pichler B.J., Hammerschmidt F., Reischl G. (2019). 4.286
2-Nitroimidazole-Furanoside Derivatives for Hypoxia Imaging – Investigation of Nucleoside Transporter Interaction, 18F-Labeling and Preclinical PET Imaging.
Pharmaceuticals 12: 31.

2018 92 Seith F., Schraml C., Reischl G., Nikolaou K., Pfannenberg C., la Fougère C., Schwenzer N. (2018). 1.420
Fast non-enhanced abdominal examination protocols in PET/MRI for patients with neuroendocrine tumors (NET): comparison to multiphase contrast-enhanced PET/CT.
Radiol. Med. 123: 860-870.

91 Mannheim J.G., Kara F., Doorduin J., Fuchs K., Reischl G., Liang S., Verhoye M., Gremse F., Mezzanotte L., Huisman M.C. (2018). 3.341
Standardization of Small Animal Imaging-Current Status and Future Prospects.
Mol. Imaging Biol. 20: 716-731.

	90	Brendle C., Hempel J.M., Schittenhelm J., Skardelly M., Reischl G., Bender B., Ernemann U., La Fougère C., Klose U. (2018). Glioma grading by dynamic susceptibility contrast perfusion and 11C-methionine positron emission tomography using different regions of interest. **Neuroradiology** 60: 381-389.	
2017	89	Schwenck J., Rempp H., Reischl G., Kruck S., Stenzl A., Nikolaou K., Pfannenberg C., La Fougère C. (2017). Comparison of 68Ga-labelled PSMA-11 and 11C-choline in the detection of prostate cancer metastases by PET/CT. **Eur. J. Nucl. Med. Mol. Imaging** 44: 92-101.	7.704
	88	Hermann D., Hirth N., Reimold M., Batra A., Smolka M.N., Hoffmann S., Kiefer F., Noori H.R., Sommer W.H., Reischl G., La Fougère C., Mann K., Spanagel R., Hansson A.C. (2017). Low μ-Opioid Receptor Status in Alcohol Dependence Identified by Combined Positron Emission Tomography and Post-Mortem Brain Analysis. **Neuropsychopharmacology** 42: 606-614.	6.544
	87	Hoffmann S.H.L., Maurer A., Reck D.I., Reischl G., Pichler B.J., Kneilling M., Griessinger C.M. (2017). Murine Lymphocyte Labeling by 64Cu-Antibody Receptor Targeting for In Vivo Cell Trafficking by PET/CT. **J. Vis. Exp.** 122: doi: 10.3791/55270.	1.184
	86	Fuchs K., Kuehn A., Mahling M., Guenthoer P., Hector A., Hartl D., Laufer S., Kohlhofer U., Quintanilla-Martinez L., Reischl G., Röcken M., Pichler B.J., Kneilling M. (2017). In vivo hypoxia PET imaging quantifies the severity of arthritic joint inflammation in line with overexpression of HIF and enhanced ROS generation. **J. Nucl. Med.** 58: 853-860.	7.439
	85	Simoncic U., Leibfarth S., Welz S., Schwenzer N., Schmidt H., Reischl G., Pfannenberg C., La Fougère C., Nikolaou K., Zips D., Thorwarth D. (2017). Comparison of DCE-MRI kinetic parameters and FMISO-PET uptake parameters in head and neck cancer patients. **Med. Phys.** 44: 2358-2368.	2.8848
	84	Kumar P., Roselt P., Reischl G., Cullinane C., Beiki D., Ehrlichmann W., Binns D., Naimi E., Yang J., Hicks R., Machulla H.J., Wiebe L.I. (2017). β-[18F]Fluoro Azomycin Arabinoside (β-[18F]FAZA): Synthesis, radiofluorination and preliminary PET imaging of murine A431 tumors. **Curr. Radiopharm.** 10: 93-101.	Cite score 1,35
	83	Welz S., Mönnich D., Pfannenberg C., Nikolaou K., Reimold M., La Fougère C., Reischl G., Mauz P.S., Paulsen F., Alber M., Belka C., Zips D., Thorwarth D. (2017). Prognostic value of dynamic hypoxia PET in head and neck cancer: Results from a planned interim analysis of a randomized phase II hypoxia-image guided dose escalation trial. **Radiother. Oncol.** 124: 526-532.	4.942
	82	Castaneda Vega S., Weinl C., Calaminus C., Wang L., Harant M., Ehrlichmann W., Thiele D., Kohlhofer U., Reischl G., Hempel J.M., Ernemann U., Quintanilla Martinez L., Nordheim A., Pichler B.J.	5.426

(2017).
Characterization of a novel murine model for spontaneous hemorrhagic stroke using in vivo PET and MR multiparametric imaging.
Neuroimage 155: 245-256.

	81	Thunemann M., Schörg B.F., Feil S., Lin Y., Voelkl J., Golla M., Vachaviolos A., Kohlhofer U., Quintanilla-Martinez L., Olbrich M., Ehrlichmann W., Reischl G., Griessinger C.M., Langer H.F., Gawaz M., Lang F., Schäfers M., Kneilling M., Pichler B.J., Feil R. (2017). Cre/lox-assisted non-invasive in vivo tracking of specific cell populations by positron emission tomography. **Nat. Commun.** 8: 444.	12.353
	80	Boeke S., Thorwarth D., Mönnich D., Pfannenberg C., Reischl G., La Fougère C., Nikolaou K., Mauz P.S., Paulsen F., Zips D., Welz S. (2017). Geometric analysis of loco-regional recurrences in relation to pre-treatment hypoxia in patients with head and neck cancer. **Acta Oncol.** 56: 1571-1576.	3.473
	79	Mönnich D., Thorwarth D., Leibfarth S., Pfannenberg C., Reischl G., Mauz P.S., Nikolaou K., La Fougère C., Zips D., Welz S. (2017). Overlap of highly FDG-avid and FMISO hypoxic tumor subvolumes in patients with head and neck cancer. **Acta Oncol.** 56: 1577-1582.	3.473
2016	78	Wiehr S., Warnke P., Rolle A.M., Schütz M., Oberhettinger P., Kohlhofer U., Quintanilla-Martinez L., Maurer A., Thornton C., Boschetti F., Reischl G., Autenrieth I.B., Pichler B.J., Autenrieth S.E. (2016). New pathogen-specific immunoPET/MR tracer for molecular imaging of a systemic bacterial infection. **Oncotarget** 7: 10990-11001.	5.168
	77	Honndorf V.S., Wiehr S., Rolle A.M., Schmitt J., Kreft L., Quintanilla-Martinez L., Kohlhofer U., Reischl G., Maurer A., Boldt K., Schwarz M., Schmidt H., Pichler B.J. (2016). Preclinical evaluation of the anti-tumor effects of the natural isoflavone genistein in two xenograft mouse models monitored by [18F]FDG, [18F]FLT, and [64Cu]NODAGA-cetuximab small animal PET. **Oncotarget** 10: 28247-28261.	5.168
	76	Schmitz J., Schwab J., Schwenck J., Chen Q., Quintanilla-Martinez L., Hahn M., Wietek B., Schwenzer N., Staebler A., Kohlhofer U., Aina O.H., Hubbard N.E., Reischl G., Borowsky A.D., Brucker S., Nikolaou K., La Fougère C., Cardiff R.D., Pichler B.J., Schmid A.M. (2016). Decoding intratumoral heterogeneity of breast cancer by multiparametric in vivo imaging: A translational study. **Cancer Res.** 76: 5512-5522.	9.122
	75	Schweifer A., Maier F.C., Ehrlichmann W., Lamparter D., Kneilling M., Pichler B.J., Hammerschmidt F., Reischl G. (2016). [18F]Fluoro-azomycin-2´-deoxy-β-d-ribofuranoside - A new imaging agent for tumor hypoxia in comparison with [18F]FAZA. **Nucl. Med. Biol.** 43: 759-769.	2.426
	74	Maier F.C., Schmitt J., Maurer A., Ehrlichmann W., Reischl G., Nikolaou K., Handgretinger R., Pichler B.J., Thaiss W.M. (2016). Correlation between positron emission tomography and Cerenkov	5.168

		luminescence imaging in vivo and ex vivo using 64Cu-labeled antibodies in a neuroblastoma mouse model. **Oncotarget** 7: 67403-67411.	
	73	Wiehr S., Rolle A.M., Warnke P., Kohlhofer U., Quintanilla-Martinez L., Reischl G., Autenrieth I.B., Pichler B.J., Autenrieth S.E. (2016). The Positron Emission Tomography Tracer 3'-Deoxy-3'-[18F]Fluorothymidine ([18F]FLT) Is Not Suitable to Detect Tissue Proliferation Induced by Systemic Yersinia Enterocolitica Infection in Mice. **PLoS One** 11(10): e0164163.	2.806
2015	72	Schwenck J., Tabatabai G., Skardelly M., Reischl G., Beschorner R., Pichler B., La Fougère C. (2015). In vivo visualization of prostate-specific membrane antigen in glioblastoma. **Eur. J. Nucl. Med. Mol. Imaging** 42: 170-171.	5.537
	71	Rolle A.M., Soboslay P.T., Reischl G., Hoffmann W.H., Pichler B.J., Wiehr S. (2015) Evaluation of the Metabolic Activity of Echinococcus multilocularis in Rodents Using Positron Emission Tomography Tracers. **Mol. Imaging Biol.** 17: 512-520.	2.569
	70	Griessinger C.M., Maurer A., Kesenheimer C., Kehlbach R., Reischl G., Ehrlichmann W., Bukala D., Harant M., Cay F., Brück J., Nordin R., Kohlhofer U., Rammensee H.G., Quintanilla-Martinez L., Schaller M., Röcken M., Pichler B.J., Kneilling M. (2015). 64Cu antibody-targeting of the T-cell receptor and subsequent internalization enables in vivo tracking of lymphocytes by PET. **Proc Natl Acad Sci USA** 112: 1161-1166.	9.423
	69	Mahling M., Fuchs K., Thaiss W.M., Maier F.C., Feger M., Bukala D., Harant M., Eichner M., Reutershan J., Lang F., Reischl G., Pichler B.J., Kneilling M. (2015). A comparative pO2 probe and [18F]-fluoro-azomycinarabino-furanoside ([18F]FAZA) PET study reveals anesthesia-induced impairment of oxygenation and perfusion in tumor and muscle. **PLoS One** 10: e0124665.	3.057
	68	Mönnich D., Welz S., Thorwarth D., Pfannenberg C., Reischl G., Mauz P.S., Nikolaou K., la Fougère C., Zips D. (2015). Robustness of quantitative hypoxia PET image analysis for predicting local tumor control. **Acta Oncol.** 54: 1364-1369.	3.730
	67	Schöls L., Reimold M., Seidel K., Globas C., Brockmann K., Hauser T.K., Auburger G., Bürk K., den Dunnen W., Reischl G., Korf H.W., Brunt E.R., Rüb U. (2015). , No parkinsonism in SCA2 and SCA3 despite severe neurodegeneration of the dopaminergic substantia nigra. **Brain** 138: 3316-3326.	10.103
2014	66	Fuchs K., Kukuk D., Mahling M., Quintanilla-Martinez L., Reischl G., Reutershan J., Lang F., Röcken M., Pichler B.J., Kneilling M. (2014). Impact of anesthetics on 3'-[18F]fluoro-3'-deoxythymidine ([18F]FLT) uptake in animal models of cancer and inflammation. **Mol Imaging.** 12: 277-287.	1.962
	65	Griessinger C.M., Kehlbach R., Bukala D., Wiehr S., Bantleon R., Cay F., Schmid A., Braumüller H., Fehrenbacher B., Schaller M., Eichner	6.160

		M., Sutcliffe J.L., Ehrlichmann W., Eibl O., Reischl G., Cherry S.R., Röcken. M., Pichler B.J., Kneilling M. (2014). In Vivo Tracking of Th1 Cells by PET Reveals Quantitative and Temporal Distribution and Specific Homing in Lymphatic Tissue. **J. Nucl. Med.** 55: 301-307.	
	64	Wehrl H.F., Martirosian P., Schick F., Reischl G., Pichler B.J. (2014). Assessment of rodent brain activity using combined [15O]H2O-PET and BOLD-fMRI. **Neuroimage** 89: 271-279.	6.357
	63	Öksüz M.Ö., Winter L., Pfannenberg C., Reischl G., Müssig K., Bares R., Dittmann H. (2014). Peptide receptor radionuclide therapy of neuroendocrine tumors with 90Y-DOTATOC: Is treatment response predictable by pre-therapeutic uptake of 68Ga-DOTATOC? **Diagn. Interv. Imaging** 95: 289-300.	2.527
	62	Kuntzsch M., Lamparter D., Brüggener N., Müller M., Kienzle G.J., Reischl G. (2014). Development and Successful Validation of Simple and Fast TLC Spot Tests for Determination of Kryptofix® 2.2.2 and Tetrabutylammonium in 18F-Labeled Radiopharmaceuticals. **Pharmaceuticals** 7: 621-633.	4.286
	61	Maier F.C., Wehrl H.F., Schmid A.M., Mannheim J.G., Wiehr S., Lerdkrai C., Calaminus C., Stahlschmidt A., Ye L., Burnet M., Stiller D., Sabri O., Reischl G., Staufenbiel M., Garaschuk O., Jucker M., Pichler B.J. (2014). Longitudinal PET-MRI reveals β-amyloid deposition and rCBF dynamics and connects vascular amyloidosis to quantitative loss of perfusion. **Nat. Med.** 20: 1485-1492.	28.223
2013	60	Fuchs K., Kohlhofer U., Quintanilla-Martinez L., Lamparter D., Kötter I., Reischl G., Röcken M., Pichler B.J., Kneilling M. (2013). In Vivo Imaging of Cell Proliferation Enables the Detection of the Extent of Experimental Rheumatoid Arthritis by 3'-Deoxy-3'-18F-Fluorothymidine and Small-Animal PET. **J. Nucl. Med.** 54: 151-158.	5.563
	59	Wiehr S., von Ahsen O., Röse L., Mueller A., Mannheim J.G., Honndorf V., Kukuk D., Reischl G., Pichler B.J. (2013). Preclinical Evaluation of a Novel c-Met Inhibitor in a Gastric Cancer Xenograft Model Using Small Animal PET. **Mol. Imaging Biol.** 15: 203-211.	2.869
	58	Wehrl H., Schwab J., Hasenbach K., Reischl G., Tabatabai G., Quintanilla-Martinez L., Jiru F., Chughtai K., Kiss A., Cay F., Bukala D., Heeren R.M., Pichler B.J., Sauter A.W. (2013). Multimodal elucidation of choline metabolism in a murine glioma model using magnetic resonance spectroscopy and 11C-choline positron emission tomography. **Cancer Res.** 73: 1470-1480.	9.284
	57	Wehrl H.F., Hossain M., Lankes K., Liu C.-C., Bezrukov I., Martirosian P., Schick F., Reischl G., Pichler B.J. (2013). Simultaneous PET-MRI reveals brain function in activated and resting state on metabolic, hemodynamic and multiple temporal scales.	28.054

Nat. Med. 19: 1184-1189.

2012	56	Fischer K., Sossi V., von Ameln-Mayerhofer A., Reischl G., Pichler B.J. (2012). In vivo quantification of dopamine transporters in mice with unilateral 6-OHDA lesions using [11C]methylphenidate and PET. **Neuroimage** 59: 2413-2422.	6.252
	55	Rensch C., Waengler B., Yaroshenko A., Samper V., Baller M., Heumesser N., Ulin J., Riese S., Reischl G. (2012). Microfluidic reactor geometries for radiolysis reduction in radiopharmaceuticals. **Appl. Radiat. Isot.** 70: 1691-1697.	1.179
	54	Schwenzer N.F., Pfannenberg C., Reischl G., Werner M.K., Schmidt H. (2012). Application of MR/PET in oncologic imaging. **Röfo.** 184: 780-787.	1.867
	53	Fuchs K., Kukuk D., Reischl G., Föller M., Eichner M., Reutershan J., Lang F., Röcken M., Pichler B.J., Kneilling M. (2012). Oxygen breathing affects 3'-deoxy-3'-18F-fluorothymidine uptake in mouse models of arthritis and cancer. **J. Nucl. Med.** 53: 823-830.	5.774
	52	Malik N., Lin X., Löffler D., Shen B., Solbach C., Reischl G., Voelter W., Machulla H.J. (2012). Synthesis of O-[2-[18 F]fluoro-3-(2-nitro-1H-imidazole-1-yl) propyl]tyrosine ([18F]FNT]) as a new class of tracer for imaging hypoxia. **J. Radioanal. Nucl. Chem.** 292: 1025-1033.	1.582
2011	51	Mätzler W., Reimold M., Schittenhelm J., Vorgerd M., Bornemann A., Kötter I., Pfannenberg C., Reischl G., Schöls L. (2011). Increased [11C]PIB-PET levels in muscle of patients with inclusion body myositis. J. Neurol. Neurosurg. **Psychiatry** 82: 1060-1062.	4.764
	50	Fischer K., Sossi V., Schmid A., Thunemann M., Maier F.C., Judenhofer M.S., Mannheim J.G., Reischl G., Pichler B.J. (2011). Noninvasive nuclear imaging enables the in vivo quantification of striatal dopamine receptor expression and raclopride affinity in mice. **J. Nucl. Med.** 52: 1133-1141.	6.381
	49	Kukuk D., Reischl G., Raguin O., Wiehr S., Judenhofer M.S., Calaminus C., Honndorf V.S., Quintanilla-Martinez L., Schönberger T., Duchamp O., Machulla H.-J., Pichler B.J. (2011). Assessment of PET Tracer Uptake in Hormone-Independent and Hormone-Dependent Xenograft Prostate Cancer Mouse Models. **J. Nucl. Med.** 52: 1654-1663.	6.381
	48	Kobiella A., Reimold M., Ulshöfer D.E., Ikonomidou V.N., Vollmert C., Vollstädt-Klein S., Rietschel M., Reischl G., Heinz A., Smolka M.N. (2011). How the serotonin transporter 5-HTTLPR polymorphism influences amygdala function: the roles of in vivo serotonin transporter expression and amygdala structure. **Transl. Psychiatry** 1: e37; doi: 10.1038/tp.2011.29.	5.724

	47	Maier F.C., Kneilling M., Reischl G., Cay F., Bukala D., Schmid A., Judenhofer M.S., Röcken M., Machulla H.J., Pichler B.J. (2011). Significant impact of different oxygen breathing conditions on noninvasive in vivo tumor-hypoxia imaging using [18F]-fluoro-azomycinarabino-furanoside ([18F]FAZA). **Radiat. Oncol**. 6: doi: 10.1186/1748-717X-6-165.	2.321
2010	46	Pfannenberg C., Aschoff P., Dittmann H., Mayer F., Reischl G., von Weyhern C., Kanz L., Claussen C.D., Bares R., Hartmann J.T. (2010). PET/CT with 18F-FLT: does it improve the therapeutic management of metastatic germ cell tumors? **J Nucl Med.** 51: 845-53.	7.022
	45	Shen B., Löffler D., Reischl G., Machulla HJ., Zeller KP. (2010). Nucleophilic [18F]fluorination and subsequent decarbonylation of methoxy-substituted nitro- and halogen-benzenes activated by one or two formyl groups. **J Labelled Compds Radiopharm**. 53:113–119.	1.096
	44	Alt K., Wiehr S., Ehrlichmann W., Reischl G., Wolf P., Pichler P.J., Elsässer-Beile U., Bühler P. (2010). High-resolution animal PET imaging of prostate cancer xenografts with three different 64Cu-labeled antibodies against native cell-adherent PSMA. **Prostate** 70: 1413-1421.	3.377
2009	43	Ferl G.Z., Dumont R.A., Hildebrandt I.J., Armijo A., Haubner R., Reischl G., Su H., Weber W.A., Huang S.C. (2009). Derivation of a compartmental model for quantifying 64Cu-DOTA-RGD kinetics in tumor-bearing mice. J. **Nucl. Med.** 50: 250-258.	6.424
	42	Shen B., Löffler D., Reischl G., Machulla H.-J., Zeller K.-P. (2009). Nucleophilic substitution of nitro groups by [18F]fluoride in methoxy-substituent ortho-nitrobezaldehydes - A systematic study. **J. Fluorine Chem.** 130: 216-224.	1.730
	41	Mätzler W., Liepelt I., Reimold M., Reischl G., Solbach C., Becker C., Schulte C., Leyhe T., Keller S., Melms A., Gasser T., Berg D. (2009). Cortical PIB binding in Lewy body disease is associated with Alzheimer-like characteristics. **Neurobiol. Dis**. 34: 107-112.	4.518
	40	Liepelt I., Reimold M., Mätzler W., Godau J., Reischl G., Gänslen A., Herbst H., Berg D. (2009). Cortical hypometabolism assessed by a metabolic ratio in Parkinson's disease primarily reflects cognitive deterioration – [18F]FDG-PET. **Mov. Disord**. 24: 1504-1511.	4.014
	39	Dumont R.A., Hildebrandt I., Su H., Haubner R., Reischl G., Czernin J.G., Mischel P.S., Weber W.A. (2009). Non-invasive imaging of αVβ3 function as a predictor of the anti-migratory and anti-proliferative effects of dasatinib. **Cancer Res.** 69: 3173-3179	7.543
	38	Elsässer-Beile U., Reischl G., Wiehr S., Bühler P., Wolf P., Alt K., Shively J., Judenhofer M.S., Machulla H.-J., Pichler B.J. (2009). PET imaging of prostate cancer xenografts with a highly specific antibody against the prostate-specific membrane antigen. **J. Nucl. Med.** 50: 606-611.	6.424

	37	Shen B., Ehrlichmann W., Uebele M., Machulla H.-J., Reischl G. (2009). Automated synthesis of n.c.a. [18F]FDOPA via nucleophilic aromatic substitution with [18F]fluoride. **Appl. Radiat. Isot.** 67: 1650-1653.	1.231
2008	36	Reimold M., Batra A., Knobel A., Smolka M.N., Zimmer A., Mann K., Solbach C., Reischl G., Schwärzler F., Gründer G., Machulla H.-J., Bares R., Heinz A. (2008). Anxiety is associated with reduced central serotonin transporter availability in unmedicated patients with unipolar major depression: A [11C]DASB PET study. **Mol. Psychiatry** 13: 606-613.	12.019
	35	Judenhofer M.S., Wehrl H.F., Newport D.F., Catana C., Siegel S.B., Becker M., Thielscher A., Kneilling M., Lichy M., Eichner M., Klingel K., Reischl G., Widmaier S., Röcken M., Nutt R.E., Machulla H.-J., Uludag K., Cherry S.R., Claussen S.D., Pichler B.J. (2008). Simultaneous PET/MRI: A new approach for functional and morphological imaging. **Nat. Med.** 14: 459-465.	27.553
	34	Stahlschmidt A., Machulla H.-J., Reischl G., Knaus E.E., Wiebe L.I. (2008). Radioiodination of 1-(2-deoxy-beta-D-ribofuranosyl)-2,4-difluoro-5-iodobenzene (dRFIB), a putative thymidine mimic nucleoside for cell proliferation studies. **Appl. Radiat. Isot.** 66: 1221-1228.	1.184
	33	Picchio M., Beck R., Haubner R., Seidl S., Machulla H.-J., Johnson T.D., Wester H.J., Reischl G., Schwaiger M., Piert M. (2008). Intratumoral spatial distribution of hypoxia and angiogenesis assessed by 18F-FAZA and 125I-Gluco-RGD autoradiography. **J. Nucl. Med.** 49: 597-605.	6.662
	32	Schönberger T., Siegel-Axel D., Bussl R., Richter S., Judenhofer M.S., Haubner R., Reischl G., Klingel K., Münch G., Seizer P., Pichler B.J., Gawaz M. (2008). The immunoadhesin glycoprotein VI-Fc regulates arterial remodelling after mechanical injury in ApoE-/- mice. **Cardiovasc. Res.** 80: 131-137.	5.947
	31	Nuber S., Petrasch-Parwez E., Winner B., Winkler J., von Hörsten S., Schmidt T., Boy J., Kuhn M., Nguyen H.P., Teismann P., Schulz J.B., Neumann M., Pichler B.J., Reischl G., Holzmann C., Schmitt I., Bornemann A., Kuhn W., Zimmermann F., Servadio A., Riess O. (2008). Neurodegeneration and motor dysfunction in a conditional model of Parkinson's disease. **J. Neurosci.** 28: 2471-2484.	7.452
2007	30	Souvatzoglou M., Grosu A., Röper B., Krause B.J., Beck R., Reischl G., Picchio M., Machulla H.-J., Wester H.-J., Piert M. (2007). Tumour Hypoxia Imaging with [18F]FAZA in Head and Neck Cancer Patients: A Pilot Study. **Eur. J. Nucl. Med. Mol. Imaging** 34: 1566-1575.	4.102
	29	Mätzler W., Reimold M., Liepelt I., Solbach C., Leyhe T., Schweitzer K., Eschweiler G.W., Mittelbronn M., Gänslen A., Uebele M., Reischl G., Gasser T., Machulla H.-J., Bares R., Berg D. (2007).	6.143

[11C]PIB binding in Parkinson's disease dementia.
Neuroimage 39: 1027-1033.

	28	Grosu A.L., Souvatzoglou M., Röper B., Dobritz M., Wiedenmann N., Jacob V., Wester H.-J., Reischl G., Machulla H.-J., Schwaiger M., Molls M., Piert M. (2007). Hypoxia imaging with FAZA-PET and theoretical considerations with regard to dose painting for individualization of radiotherapy in patients with head and neck cancer. **Int. J. Radiat. Oncol. Biol. Phys.** 69: 541-551.	5.097
	27	Shen B., Löffler D., Zeller K.-P., Übele M., Reischl G., Machulla H.-J. (2007). Decarbonylation of multi-substituted [18F]benzaldehydes for modelling syntheses of 18F-labelled aromatic amino acids. **Appl. Radiat. Isot.** 65: 1227-1231.	1.181
	26	Reimold M., Smolka M.N., Zimmer A., Batra A., Knobel A., Solbach C., Mundt A., Smoltczyk H.U., Goldman D., Mann K., Reischl G., Machulla H.-J., Bares R., Heinz A. (2007). Reduced availability of serotonin transporters in obsessive-compulsive disorder correlates with symptom severity - a [11C]DASB PET study. **J. Neural. Transm.** 114: 1603-1609.	2.969
	25	Shen B., Löffler D., Zeller K.-P., Übele M., Reischl G., Machulla H.-J. (2007). Effect of aldehyde and methoxy substituents on nucleophilic aromatic substitution by [18F]fluoride. **J. Fluorine Chem.** 128: 1461-1468.	1.498
	24	Reischl G., Dorow D.S., Cullinane C., Katsifis A., Roselt P., Binns D., Hicks R.J. (2007). Imaging of tumor hypoxia with [124I]IAZA in comparison with [18F]FMISO and [18F]FAZA – First small animal PET results. **J. Pharm. Pharmaceut.** Sci. 10: 203-211	2.042
	23	Plewnia C., Reimold M., Najib A., Brehm B., Reischl G., Plontke S., Gerloff C. (2007). Dose-dependent attenuation of auditory phantom perception (tinnitus) by PET-guided repetitive transcranial magnetic stimulation. **Hum. Brain Mapp.** 28: 238-246.	4.317
	22	Plewnia C., Reimold M., Najib A., Reischl G., Plontke S.K., Gerloff C. (2007). Moderate therapeutic efficacy of PET-navigated repetitive transcranial magnetic stimulation against chronic tinnitus: a randomised, controlled pilot study. **J. Neurol. Neurosurg. Psychiatry** 78: 152-156.	3.122
	21	Reimold M., Smolka M.N., Schumann G., Zimmer A., Wrase J., Mann K., Hu X.-Z., Goldman D., Reischl G., Solbach C., Machulla H.-J., Bares R., Heinz A. (2007). Midbrain serotonin transporter binding potential measured with [11C]DASB is affected by serotonin transporter genotype. **J. Neural Transm.** 114: 635-639.	2.544
2006	20	Breit S., Reimold M., Reischl G., Klockgether T., Wüllner U. (2006). [11C]d-threo-methyl-phenidate PET in patients with Parkinson's disease and essential tremor.	2.544

J. Neural Transm. 113: 187-193.

	19	Reischl G., Blocher A., Wei R., Ehrlichmann W., Kuntzsch M., Solbach C., Dohmen B.M., Machulla H.-J. (2006). Simplified, Automated Synthesis of 3'-[18F]Fluoro-3'-Deoxy-Thymidine ([18F]FLT) and Simple Method for Metabolite Analysis in Plasma. **Radiochim. Acta** 94: 447-451.	0.846
2005	18	Kienzle G.J., Reischl G., Machulla H.-J. (2005). Electrochemical Radiofluorination. 3. Direct labeling of phenylalanine derivatives with [18F]fluoride after anodic oxidation. **J. Label. Compd. Radiopharm**. 48: 259-273.	0.829
	17	Piert M., Machulla H.-J., Picchio M., Reischl G., Ziegler S., Kumar P., Wester H.-J., Beck R., McEwan A.J.B., Wiebe L., Schwaiger M. (2005). Hypoxia-specific Tumor Imaging with Fluorine-18 Labeled Fluoroazomycin Arabinoside ([18F]FAZA). **J. Nucl. Med.** 46: 106-113.	4.684
	16	Solbach C., Übele M., Reischl G., Machulla H.-J. (2005). Efficient Synthesis of C-11 Labeled Uncharged Thioflavin T Derivatives Using [C-11]Methyltriflat in a Remote Controlled Module. **Appl. Radiat. Isot.** 62: 591-595.	0.757
	15	Reischl G., Ehrlichmann W., Bieg C., Solbach C., Kumar P., Wiebe L.I., Machulla H.-J. (2005). Preparation of the Hypoxia Imaging PET Tracer [18F]FAZA: Reaction Parameters and Automation. **Appl.Radiat. Isot.** 62: 897-901.	0.757
	14	Eschmann S.M., Paulsen F., Reimold M., Dittmann H., Welz S., Reischl G., Machulla H.-J., Bares R. (2005). Prognostic impact of hypoxia-imaging with 18F-Misonidazole-PET in non-small cell lung cancer and head-and-neck cancer prior to radiotherapy. **J. Nucl. Med.** 46: 253-260.	4.684
	13	Hodé Y., Reimold M., Demaziéres A., Reischl G., Bayle F., Nuss P., Hameg A., Dib M., Macher J.P. (2005). A positron emission tomography (PET) study of cerebral dopamine D2 and serotonin 5-HT2A receptor occupancy in patients treated with cyamemazine (TERCIAN®). **Psychopharmacology** 180: 377-384.	3.994
2004	12	Reimold M., Müller-Schauenburg W., Becker G.A., Reischl G., Dohmen B.M., Bares R. (2004). Non-invasive Assessment of Distribution Volume Ratios and Binding Potential: Tissue Heterogeneity and interindividually averaged Time-Activity Curves. Eur. **J. Nucl. Med. Mol. Imaging** 31: 564-577.	3.935
	11	Smyczek-Gargya B., Fersis N., Dittmann H., Vogel U., Reischl G., Machulla H.-J., Wallwiener D., Bares R., Dohmen B.M. (2004). PET with [18F]Fluorothymidine for Imaging of Primary Breast Cancer: A Pilot Study. **Eur. J. Nucl. Med . Mol. Imaging** 31: 720-724.	3.935
	10	Solbach C., Reischl G., Machulla H.-J. (2004). Determination of Reaction Parameters for the Synthesis of the Serotonin Transporter Ligand [11C]DASB: Application in a Remote-	1.033

		Controlled High Yield Synthesis. **Radiochim. Acta.** 92: 341-344. (IF = 1,033)	
	9	Reischl G., Bieg C., Schmiedl O., Solbach C., Machulla H.-J. (2004). Highly Efficient Automated Synthesis of [11C]Choline for Multi Dose Utilization. **Appl. Radiat. Isot.** 60: 835-838.	1.000
	8	Hummerich R., Reischl G., Ehrlichmann W., Machulla H.-J., Heinz A., Schloss P. (2004). DASB – In Vitro Binding Characteristics on Human Recombinant Monoamine Transporters with Regard to its Potential as PET-tracer. **J. Neurochem.** 90: 1218-1226.	4.824
2003	7	Reischl G., Kienzle, G.J., Machulla, H.-J. (2003): Electrochemical radiofluorination. Part 2. Anodic monofluorination of substituted benzenes using [18F]fluoride. **Appl. Radiat. Isot.** 58: 679-683	0.690
2002	6	Reischl G., Rösch F., Machulla H.-J. (2002): Electrochemical separation and purification of yttrium-86. **Radiochim. Acta** 90: 225-228.	0.809
	5	Reischl G., Ehrlichmann W., Machulla H.-J. (2002): Electrochemical transfer of [18F]fluoride from [18O]water into organic solvents ready for labeling reactions. **J. Radioanal. Nucl. Chem.** 254(1): 29-31.	0.502
	4	Eschmann, S. M., Reischl, G., Bilger, K., Kupferschläger, J., Thelen, M. H., Dohmen, B. M., ...Bares, R. (2002). Evaluation of dosimetry of radioiodine therapy in benign and malignant thyroid disorders by means of iodine-124 and PET. **European journal of nuclear medicine and molecular imaging,** 29, 760-767.	3.568
	3	Reischl, G., Kienzle, G., Machulla, H. J. (2002): Electrochemical radiofluorination: Labeling of benzene with [18 F] fluoride by nucleophilic substitution. **Journal of radioanalytical and nuclear chemistry**, 254(2), 409-411.	0.502
1998	2	Reischl, G., El-Mobayed, M., Beißwenger, R., Regier, K., Maichle-Mössmer, C., Rieker, A. (1998): Oxidation-induced acyl group transfer from hydroquinone esters to nucleophiles. **Zeitschrift für Naturforschung** B, 53(7), 765-773.	0.731
1996	1	Reischl, G., Rieker, A., Maichle-Mössmer, C., Abram, S. (1996): Base-Catalyzed Dehalogenation of 2, 6-Di-tert-butyl-4-iodophenol Formation and Structure of a New Oxocyclohexadienylidene Bisphenol. **Liebigs Annalen,** 1996(7), 1183-1186.	1.578

116 Publications in international, peer-reviewed journals

h-Index: **37** (Scopus)

Review Articles

Year	Number	Title	IF
2021	5	Reischl G. and Benešová M. (2021): Production of radionuclides: Cyclotrons and reactors. Elsevier Reference Module in Biomedical Sciences.	N.A.
2019	4	Reischl G. Special Issue (2019): Targets, Tracers and Translation Novel Radiopharmaceuticals Boost Nuclear Medicine. Pharmaceuticals (Basel). 2019 Jul 18;12(3):111.	4.286
2018	3	Kienzle, G.J. and Reischl, G. (2018): Herstellung von PET-Radiopharmaka in der Klinik–Aktuelle Rahmenbedingungen und Qualitätssicherung. Nuklearmediziner, 41(04), 317-325.	N.A.
2009	2	Bares, R., Reischl, G. and Eschmann, S.M. (2009): Hypoxia imaging. Nuklearmediziner, 32(2), 164-169.	N.A.
2000	1	Reischl, G. and Machulla, H.J. (2000). Trends in radiopharmacy. Nuklearmediziner, 23(5), 349-354.	N.A.

Book Chapters

DAB-Kommentar, Wiss. Erläuterungen zum Deutschen Arzneibuch, Wiss. Verlagsgesellschaft mbH, Stuttgart, (Scientific commentary to the German Pharmacopoe; Contributions to Monographs of Radioactive Pharmaceuticals), 2017.

Hunnius pharmazeutisches Wörterbuch, 9. Auflage, 2004, Hrsg. P.T. Ammon, Walter de Gruyter Verlag, Berlin, New York, Beiträge zu den Fachgebieten Radioaktivität und Radiopharmaka.

Invited Talks

2021	XXXV Brazilian Congress of Nuclear Medicine, XXVIII Congress of the Association of Latin-American Societies of Biology and Nuclear Medicine (ALASBIMN), Virtual “Radiolabeled Biologicals for PET – Preclinical Development and Clinical Application“
2020	ECA GMP Academy, Radiopharmaceuticals, Virtual Conference “Radiation Protection in Radiopharmaceutical Production“ “Validation of Analytical Methods”
2019	Opening Symposium CUP Laboratories, Radeberg „Neue Wege in nuklearmedizinischer Diagnostik und Therapie durch radioaktiv markierte Biomoleküle”
2019	ECA GMP Academy, Radiopharmaceuticals, Wien “Validation of Analytical Methods”
2018	Peter MacCallum Cancer Institute, Melbourne (AUS) “Radiopharmaceutical Developments Targeting Antigens for Imaging in Oncology and Infectious Diseases“
2018	Monash University, Melbourne (AUS) “Targets, Tracers and Translation – Radiolabeled Biomolecules on the Move“

2018	DKFZ, Heidelberg „Radiomarkierte Biomoleküle – Präklinische Entwicklung und klinische Anwendung“
2017	Institut für Kernchemie, Universität Mainz „Kohlenstoff-11 – Totgesagte leben länger. Möglichkeiten eines vielseitigen PET-Nuklids in Forschung und klinischer Translation“
2017	Pre-Conference, Annual Meeting DGN, Dresden „GMP-konforme Herstellung von ^{68}Ga-markierten PET-Radiopharmaka für die Patientenversorgung und im Rahmen von klinischen Studien“
2017	ECA GMP Academy, Radiopharmaceuticals, Wien “Radiation Protection in Radiopharmaceutical Production“
2016	TÜV-Congress, Tübingen „Positronen-Emissions-Tomographie – Radioaktive Arzneimittel zur Molekularen Bildgebung für Forschung und Klinik“
2016	IAEA Radiopharmacy Meeting, Wien „Small Molecules and Biomolecules – Various Aspects of the Preclinical Evaluation of Radiopharmaceuticals“
2016	Forschungszentrum Jülich, 50 Jahre Nuklearchemie, Jülich „Translation and Theranostics – Radiolabeled Antibodies on the Move“
2016	Vereinigung Südwestdeutscher Radiologen und Nuklearmediziner, Karlsruhe „Das Tracerprinzip“
2015	Image-Guided Interventions Conference, Mannheim “Translation neuentwickelter PET Biomarker in die Klinik”
2015	Aseptikon, Mannheim “Strahlenschutzaspekte bei der Herstellung von Radiopharmaka”
2015	Südwestdeutsche Gesellschaft für Nuklearmedizin, Tübingen „Neues aus der Radiopharmazie“
2013	University of Melbourne, Melbourne (AUS) “Copper-64 – A Story of Success in PET”
2012	Nuclear Research Centre (IPEN) São Paulo, Brazil Various Talks on Radiopharmaceutical Research and Development

and more

Reviewer

Since 2009	Reviewer of Grant Applications for DFG, ÖNB, Tiroler Wissenschaftsfond
Since 2012	External Reviewer for Dissertations (University of Vienna (A), University of Pretoria (RSA), University of Melbourne (AUS))

Journals:

Pharmaceuticals

European Journal of Nuclear Medicine and Molecular Imaging

Nuclear Medicine and Biology

Cancer Biotherapy

Chemistry and Medicinal Chemistry

Journal of Medicinal Chemistry

Applied Radiation and Isotopes

Journal of Labelled Compounds and Radiopharmaceuticals

Journal of Radioanalytical and Nuclear Chemistry

and more

Professional Memberships

Since 2019	Deutsche Pharmazeutische Gesellschaft (DPhG)
Since 2014	European Association of Nuclear Medicine (EANM)
Since 2008	Society of Radiopharmaceutical Sciences (SRS)
Since 2007	Deutsche Gesellschaft für Nuklearmedizin (DGN)
Since 1997	Arbeitsgemeinschaft Radiochemie/-pharmazie der DGN
Since 1994	Gesellschaft Deutscher Chemiker (GDCH)

Awards and Honors

2019 - 2022	Member of Steering Committee of the Excellence Cluster “iFIT”, University of Tübingen
Since 2019	Member of the Board of the German Pharmaceutical Society (DPhG)
Since 2019	Chair of the Consortium “Radiopharmacy” of DPhG
2012	Elsevier, Applied Radiation and Isotopes, *JARI Enterprise Award 2012* („For outstanding work in radiation sciences“)
Since 2012	Expert for IAEA
2006 - 2022	Member of the Managing Board of the Consortium “Radiochemistry / Radiopharmacy” within the German Society of Nuclear Medicine (DGN)